MDA 2023: Patients typically need wheelchairs within 2 years of onset
On average, a person with amyotrophic lateral sclerosis (ALS) will require a wheelchair to get around within two years…
Articles by Marisa Wexler, MS
FDA panel votes in favor of tofersen biomarker data
Changes in neurofilament light chain (NfL) levels — a biomarker of nerve cell damage — were deemed by an advisory…
MDA 2023: Expansion in WDR7 gene linked to increased ALS risk
A potential new genetic risk factor for amyotrophic lateral sclerosis (ALS) has been discovered by researchers at the University…
MDA 2023: COYA 302 therapy slows ALS progression in early trial
Four people with amyotrophic lateral sclerosis (ALS) each experienced a marked slowing in disease progression with COYA 302, an…
MDA 2023: Walking, other functions retained longer on Radicava
Amyotrophic lateral sclerosis (ALS) patients treated with Radicava (edaravone) tend to go longer before reaching disease milestones such…
Radicava ORS fares well in Phase 3 clinical trial
Note: This story was updated March 10, 2023, to correct a secondary headline to note the therapy was tracked for…
Significant differences between sexes seen in ALS gene study results
The gene expression profiles of motor neurons — the specialized nerve cells that control movement and are lost in…
Screens in diverse cell models in lab ID 2 new ALS therapeutic targets
A team of U.S. researchers have identified two proteins in the lab — PIKFYVE and SYF2 — that may each…
NINDS sets new priorities for ALS research to improve life quality
A group of experts, led by scientists from the National Institute of Neurological Disorders and Stroke (NINDS), has published a…
Motor neurons’ size may make them vulnerable to ALS
Human motor neurons rely on a specialized molecular architecture to help support their large size, which may partially explain why…